Anticancer activities of manganese-based photoactivatable CO-releasing complexes (PhotoCORMs) with benzimidazole derivative ligands

Benzimidazole scaffold as a potent anticancer agent with different mechanisms of action (2016-2023)

Benzimidazole scaffolds have potent anticancer activity due to their structure similarity to nucleoside. In addition, benzimidazoles could function as hydrogen donors or acceptors and bind to different drug targets that participate in cancer progression. The literature had many anticancer agents containing benzimidazole cores that gained much interest. Provoked by our endless interest in benzimidazoles as anticancer agents, we summarized the successful trials of the benzimidazole scaffolds in this concern. Moreover, we discuss the substantial opportunities in cancer treatment using benzimidazole-based drugs that may direct medicinal chemists for a compelling future design of more active chemotherapeutic agents with potential clinical applications. The uniqueness of this work lies in the highlighted benzimidazole scaffold hybridization with different molecules and benzimidazole-metal complexes, detailed mechanisms of action, and the IC50 of the developed compounds determined by different laboratories after 2015.

Benzimidazole(s): synthons, bioactive lead structures, total synthesis, and the profiling of major bioactive categories

Benzimidazole, a fused bicyclic compound with benzene and pentacyclic 1,3-diazole moeities, has a simple aromatic heterocyclic structure. The moiety has become an indispensable anchor for the development of new pharmacologically active products, and has yielded several therapeutic agents with anticancer, antihypertensive, antimicrobial, antifungal and antiulcer effects. Benzimidazoles, as synthetically feasible and pharmacophoric synthons, have been relentlessly pursued for the preparation of new analogues and derivatives, and they have successfully developed into some of the most sought-after and vital pharmacophores for drug discovery. The use of varied substituents and differing patterns around the benzimidazole nucleus has provided a wide spectrum of biological activities. In addition, the benzimidazole moiety constitutes a building block for the production of several drugs, drug candidates, new chemical entities, and lead molecules. The importance of this nucleus for bioactivity, e.g., antibacterial, antitubercular, antidiabetic, anticancer, antifungal, anti-inflammatory, analgesic, antioxidant, antihistaminic, and antimalarial activity, has led us to take note and provide an overview of the synthetic development approaches for various benzimidazole derivatives together with their biological actions. This review is projected to further assist in the design and development of new benzimidazole-based compounds for new and optimized pharmacologically active products towards new drug-development strategies.

A comprehensive survey of Mn(I) carbonyls as CO-releasing molecules reported over the last two decades

Over the last two decades, manganese(I) carbonyl complexes have been widely investigated as carbon monoxide releasing molecules (CORMs) to transfer small quantities of CO to biological targets to have beneficial impacts such as preventing ischemia reperfusion injury and reducing organ transplant rejection. Furthermore, these complexes exhibit beneficial anti-coagulative, anti-apoptotic, anti-inflammatory, and anti-proliferative properties. Owing to their highly controlled substitution chemistry and oxidative durability, Mn(I) carbonyl moieties were combined with a wide range of auxiliary ligands, including biomolecules. This review focused on tri- and tetracarbonyl Mn(I) complexes that were exposed to light, changed the redox status, or underwent thermal activation to release carbon monoxide. Kinetic parameters, stability in the dark, number of CO release equivalents, CO detection tools, and the nature of solvents used in the studies are reported and tabulated. An overview of all the previously published Mn(I) CORMs is specifically provided to define the method of action of these promising biologically active compounds and discuss their possible therapeutic applications in relation to their CO-releasing and biocompatibility characteristics.

Metal-based carbon monoxide releasing molecules with promising cytotoxic properties

Carbon monoxide, the "silent killer" gas, is increasingly recognised as an important signalling molecule in human physiology, which has beneficial biological properties. A particular way of achieving controlled CO administration is based on the use of biocompatible molecules that only release CO when triggered by internal or external factors. These approaches include the development of pharmacologically effective prodrugs known as CO releasing molecules (CORMs), which can supply biological systems with CO in well-regulated doses. An overview of transition metal-based CORMs with cytotoxic properties is here reported. The mechanisms at the basis of the biological activities of these molecules and their potential therapeutical applications with respect to their stability and CO releasing properties have been discussed. The activation of metal-based CORMs is determined by the type of metal and by the nature and features of the auxiliary ligands, which affect the metal core electronic density and therefore the prodrug resistance towards oxidation and CO release ability. A major role in regulating the cytotoxic properties of these CORMs is played by CO and/or CO-depleted species. However, several mysteries concerning the cytotoxicity of CORMs remain as intriguing questions for scientists.

Synthesis, structures, DFT calculations, and catalytic application in the direct arylation of five-membered heteroarenes with aryl bromides of novel palladium-N-heterocyclic carbene PEPPSI-type complexes

A new series of Pd-catalysts was synthesized and fully characterized via spectroscopic methods and the Pd–NHC complexes were evaluated via the direct arylation process.

Light-Activated Carbon Monoxide Prodrugs Based on Bipyridyl Dicarbonyl Ruthenium(II) Complexes

Two photoactivatable dicarbonyl ruthenium(II) complexes based on an amide-functionalised bipyridine scaffold (4-position) equipped with an alkyne functionality or a green-fluorescent BODIPY (boron-dipyrromethene) dye have been prepared and used to investigate their light-induced decarbonylation. UV/Vis, FTIR and 13 C NMR spectroscopies as well as gas chromatography and multivariate curve resolution alternating least-squares analysis (MCR-ALS) were used to elucidate the mechanism of the decarbonylation process. Release of the first CO molecule occurs very quickly, while release of the second CO molecule proceeds more slowly. In vitro studies using two cell lines A431 (human squamous carcinoma) and HEK293 (human embryonic kidney cells) have been carried out in order to characterise the anti-proliferative and anti-apoptotic activities. The BODIPY-labelled compound allows for monitoring the cellular uptake, showing fast internalisation kinetics and accumulation at the endoplasmic reticulum and mitochondria.

Cytotoxicity of Mn-based photoCORMs of ethynyl-α-diimine ligands against different cancer cell lines: The key role of CO-depleted metal fragments

A series of tricarbonyl manganese complexes bearing 4-ethynyl-2,2'-bipyridine and 5-ethynyl-1,10-phenanthroline α-diimine ligands were synthetized, characterized and conjugated to vitamin B₁₂, previously used as a vector for drug delivery, to take advantage of its water solubility and specificity toward cancer cells. The compounds act as photoactivatable carbon monoxide-releasing molecules rapidly liberating on average ca. 2.3 equivalents of CO upon photo-irradiation. Complexes and conjugates were tested for their anticancer effects, both in the dark and following photo-activation, against breast cancer MCF-7, lung carcinoma A549 and colon adenocarcinoma HT29 cell lines as well as immortalized human bronchial epithelial cells 16HBE14o- as the non-carcinogenic control. Our results indicate that the light-induced cytotoxicity these molecules can be attributed to both their released CO and to their CO-depleted metal fragments including liberated ligands.

Single-Pot Self-Assembly of Heteroleptic Mn(I)-Based Aminoquinonato-Bridged Ester/Amide-Functionalized Dinuclear Metallastirrups: Potential Anticancer and Visible-Light-Triggered CORMs

Multicomponent self-assembly of Mn₂(CO)₁₀, a bis-chelating aminoquinonato (ON∩ON) bridge (L), and an ester/amide-functionalized flexible neutral ditopic linker (L') has resulted into the formation of M₂LL'-type manganese(I)-based dinuclear metallastirrups of general formula [{(CO)₃Mn(μ-η⁴-L)Mn(CO)₃}(μ-L')] (1-10). Compounds 1-10 were accomplished via orthogonal bonding of the aminoquinone ligand (2,5-bis(n-butylamino)-1,4-benzoquinone/2,5-bis(phenethylamino)-1,4-benzoquinone) and ditopic pyridyl ligand to manganese carbonyl. The resultant metallastirrups were characterized using elemental analyses and IR, UV-vis, ¹H NMR, and electrospray ionization-mass spectroscopic techniques. The molecular structure of 6 was confirmed by single-crystal X-ray diffraction methods. Furthermore, molecular recognition capabilities of 1, 5, 7, and 9 were evaluated with aromatic compounds containing hydroxy/amine functionalities. Anticancer activities of compounds 1-3, 5-7, 9, and 10 were investigated against three cancer cell lines, that is, lung (A549), colon (HCT-15), and cervical (HeLa) as well as on normal cells (HEK 293). Compound 9 showed a broad-spectrum inhibition toward these cancer cells upon exposure to visible light. The myoglobin assay was performed using UV-vis absorption spectroscopy to investigate the visible-light-triggered CO release from 5 and 9 that could be related to their ability to effectively inhibit cancer cells. In addition, morphological studies confirmed the induction of autophagy due to the treatment of cancer cells using compound 9.

Vesicles Functionalized with a CO-Releasing Molecule for Light-Induced CO Delivery

In this paper, a new type of methodology to deliver carbon monoxide (CO) for biological applications has been introduced. An amphiphilic manganese carbonyl complex (1.Mn) incorporated into the 1,2-distearoyl-sn-glycero-3-phosphocholine lipid vesicles has been reported first time for the photoinduced release of CO. The liposomes (Ves-1.Mn) gradually released CO under light at 365 nm over a period of 50 min with a half-time of 26.5 min. The CO-releasing ability of vesicles appended with 1.Mn complexes has been confirmed by myoglobin assay and infrared study. The vesicles appended with 1.Mn have the advantages of biocompatibility, water solubility, and steady and slow CO release. This approach could be a rational approach for applying various water-insoluble photoinduced CO donors in aqueous media by using vesicles as a nanocarrier for CO release.